Abstract P1-16-05: Oraxol + Encequidar (OPac+E) vs IV paclitaxel (IVPac) in the treatment of patients with metastatic breast cancer (mBC) (Study KX-ORAX-001): Subgroup survival analysis of patients with hepatic dysfunction

MLA

Gerardo Umanzor, et al. “Abstract P1-16-05: Oraxol + Encequidar (OPac+E) vs IV Paclitaxel (IVPac) in the Treatment of Patients with Metastatic Breast Cancer (MBC) (Study KX-ORAX-001): Subgroup Survival Analysis of Patients with Hepatic Dysfunction.” Cancer Research, vol. 82, Feb. 2022, pp. P1-16. EBSCOhost, https://doi.org/10.1158/1538-7445.sabcs21-p1-16-05.

APA

Gerardo Umanzor, Hope S Rugo, Francisco J Barrios, R H Vasallo, Marco A Chivalan, S Bejarano, Julio Roberto Ramirez, Luis Fein, R D Kowalyszyn, D L Cutler, D Kramer, H Wang, & R MF Kwan. (2022). Abstract P1-16-05: Oraxol + Encequidar (OPac+E) vs IV paclitaxel (IVPac) in the treatment of patients with metastatic breast cancer (mBC) (Study KX-ORAX-001): Subgroup survival analysis of patients with hepatic dysfunction. Cancer Research, 82, P1-16. https://doi.org/10.1158/1538-7445.sabcs21-p1-16-05

Chicago

Gerardo Umanzor, Hope S Rugo, Francisco J Barrios, R H Vasallo, Marco A Chivalan, S Bejarano, Julio Roberto Ramirez, et al. 2022. “Abstract P1-16-05: Oraxol + Encequidar (OPac+E) vs IV Paclitaxel (IVPac) in the Treatment of Patients with Metastatic Breast Cancer (MBC) (Study KX-ORAX-001): Subgroup Survival Analysis of Patients with Hepatic Dysfunction.” Cancer Research 82 (February): P1-16. doi:10.1158/1538-7445.sabcs21-p1-16-05.